Selen Güler1, Yeliz Çağan Appak1, Şenay Onbaşı Karabağ1, Betül Aksoy1, Sinem Kahveci1, Melis Köse2, Esra Er2, Maşallah Baran1

1Katip Çelebi University & Sbu Tepecik Training And Research Hospital, Pediatric Gastroenterology Hepatology And Nutrition, İzmir, Turkiye
2Katip Çelebi University & Sbu Tepecik Training And Research Hospital, Pediatric Metabolism Diseases, İzmir, Turkiye

Keywords: Gaucher's disease, adolescence, metabolic disease


Gaucher's disease (GD) is an autosomal recessive lysosomal lipid storage disorder caused due to insufficient activity of the enzyme beta-glucocerebrosidase. Type 1 GD may present at any age but manifests in childhood in more than half of patients. In this case report, an adolescent who applied to our gastroenterology outpatient clinic with dyspeptic complaints and was diagnosed with type 1 GD is presented to draw attention to rare metabolic diseases. A 14-year-old girl complaining of abdominal and bone pain was admitted to the hospital. Erlenmeyer flask deformity was detected on the direct knee radiograph of the patient, as well as thrombocytopenia, ferritin elevation and hepatosplenomegaly. A preliminary diagnosis of Gaucher disease was considered upon detection of low levels of beta glucocerebrosidase enzyme for our patient. The homozygous variant was detected in the GBA gene NM_000157.4:c.1226A>G (p.Asn409Ser) and diagnosed as Type 1 GD. When evaluating patients, it is important to remember that some rare metabolic diseases can be observed in older children. Our patient was diagnosed with Type 1 GD at an adolescent age, and treatment was started. Currently, improvements in clinical manifestations can be achieved with existing treatments. Therefore, it is crucial to diagnose the disease at an early stage and begin the necessary treatment.


Gaucher's disease (GD) is a rare autosomal recessive lysosomal lipid storage disorder caused due to insufficient activity of the enzyme beta-glucocerebrosidase (1). Along with the accumulation of glucocerebrosides in monocytes and macrophages, liver, spleen and bone marrow involvement can be observed. GD is divided into three main types. Type 1 is the most common form, accounting for up to 90% of all cases. Unlike other types, it has no neurological involvement. Type 2 is called the infantile or acute neuropathic form, and type 3 is called the juvenile subacute neuropathic form. Type 1 GD is defined as an adult type, but its clinical manifestations can be observed in many individuals, from symptomatic infants to asymptomatic adults (2).

In this case report, an adolescent who was admitted to our gastroenterology outpatient clinic with abdominal pain and dyspeptic complaints and diagnosed with type 1 GD is presented to draw attention to rare metabolic diseases and raise awareness.

Case Report

A 14-year-old girl was admitted to our paediatric gastroenterology outpatient clinic with complaints of weakness, nausea, burning in the stomach and abdominal pain in the epigastric region. It was learned that the frequency of complaints of the patient had been increasing for the last year. When her history was evaluated in detail, she described weakness and pain in her entire body, especially in the kneecap, heel and fingers. It was learned that there was a first-degree kinship between the patient’s parents with no known disease in the past.

The patient’s body weight and height were at the 90-97th percentile and 97th percentile, respectively. On physical examination, it was observed that Traube’s space was closed, the spleen was palpable 1 cm below the left costal margin, the liver was palpable by 2 cm, and epigastric tenderness was present. The neurological examination and other physical examination findings of the patient, who had tenderness in the knee and elbow joints and fingers by palpation, were within the usual limits.

The following were also detected: 12,4 g/dL haemoglobin, 9900/mm3 leukocyte count, 96000 mm3 platelet count, 1312 ng/mL ferritin, 36 U/L aspartate aminotransferase and 30 U/L alanine aminotransferase. Hepatitis B, C and HIV serology were negative. Moreover, a peripheral blood smear test showed 60% polymorphonuclear leukocytes, 32% lymphocytes, 8% monocytes, and clusters of 6-7 platelets, some of which were large in appearance. No atypical cells were observed.

Direct radiography of the femur revealed Erlenmeyer flask deformity (Figure 1), and abdominal MRI revealed signal changes in the liver parenchyma consistent with hemochromatosis. Bone densitometry (lumbar and femoral neck) was compatible with osteopenia.

In a liver biopsy, mild inflammatory cell reactions, including lymphoplasmacytic cells in portal areas, focal balloon degeneration in hepatocytes, nuclear glycogenation, regenerative changes, and mild (Grade 2/4) iron accumulation with a Prussian blue stain were reported (Figure 2). Bone marrow biopsy showed Gaucher cells.

Genetic tests for hemochromatosis were normal in the case. The homozygous variant NM_000157.4:c.1226A>G (p.Asn409Ser) was detected in the GBA gene. Neurological and eye examinations were normal, and we started imiglucerase treatment on the patient after the diagnosis of type 1 GD. She has been taking imiglucerase treatment at a dose of 30 ıu/kg for two years. The homozygous mutation was also found in one brother with family screening. The consent from the parents’ of the participant was obtained in this case study.


Gaucher’s disease is a lipid storage disease with an incidence ranging from 1/4000-1/10000 (3). It was first described by Ernest Gaucher in 1882. Type 1 non-neuropathic GD, the most common of the three types of disease, may occur at any age. Our patient was admitted with dyspeptic complaints at the age of 14 and was able to get a diagnosis when she was evaluated in detail with the history and physical examination findings in our clinic. Hepatosplenomegaly, haematological disorders and bone lesions are the main pathologies in patients with type 1 Gaucher disease. The earlier the age of onset of symptoms, the worse the prognosis. The prognosis is negatively affected due to neurological involvement in type 2 and type 3 GD, and both types have a deficiency of the beta glucocerebrosidase enzyme, but their mutations are different (4,5,6).

The hallmark of Gaucher disease is the presence of lipid-laden Gaucher cells in organs, such as bone marrow, spleen and liver. Although these cells seem unique in morphologic features and metabolism, their exact role in the pathology of GD remains largely unknown (7). Phenotypic changes may be observed depending on the age of manifestation of symptoms (8). Hepatosplenomegaly on physical examination in a patient with bone pain as a starting symptom and the detection of anaemia and thrombocytopenia in laboratory studies are stimuli for diagnosing GD. Cases where massive splenomegaly was detected in childhood, splenectomy was performed due to hypersplenism and GD was diagnosed in adulthood were also reported (3,9). Dyspeptic complaints at the forefront, bone pain, hepatosplenomegaly on physical examination and thrombocytopenia found through laboratory tests made the patient think she had GD, and further examinations were performed.
Although bone involvement is most common and severe in type 3 GD, bone involvement is also common in type I GD. The most common of these is the Erlenmeyer flask deformity of the distal femur, which is seen as cortical thinning and loss of concavity in the distal femur (2). More rarely, osteopenia, bone necrosis and bone infarcts can also be observed. (4, 10, 11). In our patient, the detection of Erlenmeyer flask deformity in the femur, which is suggestive of GD, was a guide regarding diagnosis.

Iron accumulation is observed in GD for unclarified reasons. Studies have shown that mild chronic inflammation in patients may lead to high ferritin levels, increased hepcidin transcription and subsequent storage of ferritin in macrophages (12). Ferritin levels were high in the examinations of our patient, and iron accumulation was observed in the histopathological examination of the liver biopsy.

When evaluating patients, it should be noted that some rare metabolic diseases can be observed in older children with different clinical manifestations. As a result of a detailed evaluation of our case, we were able to diagnose type 1 GD at an adolescent age and begin enzyme replacement therapy for our patient. Significant improvement in hepatosplenomegaly, haematological disorders and skeletal findings can be achieved with current treatments (2). Therefore, it is important to think about the disease, determine the diagnosis at an early stage and begin treatment.

Cite this article as: Güler S, Cagan Appak Y, Onbasi Karabag S, Aksoy B, Kahveci S, Kose M, et al. Gaucher Disease Diagnosed during Adolescence. Pediatr Acad Case Rep. 2023;2(1):28-31.

Conflict of Interest

The authors declared no conflicts of interest with respect to authorship and/or publication of the article.

Financial Disclosure

The authors received no financial support for the research and/or publication of this article.


We thank to Birsen Gizem Özamrak from the Pathology Department of Tepecik Training and Research Hospital.


  1. Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med 2012; 14(77): 273-81.
  2. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017; 18(2): 441.
  3. Çağlıyan AG, Bilgir O. Erişkin yaşta tanı alan Gaucher hastalıklı bir olgu. Ege Tıp Dergisi 2015; 54(4): 196-8.
  4. Elstein D, Abrahamov A, Hadas-Halpern, A Zimran. Gaucher's disease. Lancet 2001; 358(9278): 324-7.
  5. Beulter E. Gaucher disease: Multipl lessons from a single gene disorder. Acta Paediatr 2006; 95(451): 103-9.
  6. Grabowski GA, Andria G, Baldellou A, Pauline E Campbell, Joel Charrow, Ian J Cohen et al. Gaucher disease: Presentation, diagnosis and assessment. Eur J Pediatr 2004; 163(2): 58-66.
  7. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004; 122(3): 359-69.
  8. Alfonso P, Cenarro A, Perez-Calvo JI, M Giralt, P Giraldo, M Pocoví. Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations. Blood Cells Mol Dis 2001; 27(5): 882-91.
  9. Selim Aydemir, Yücel Üstündağ, Mehmet Sert, Hayriye Sayarlıoğlu, Sibel Yenidünya, Gamze Numanoğlu et al. Gaucher hastalığı; iki olgu. Akademik Gastroenteroloji Dergisi 2005; 4 (1): 60-3.
  10. Bembi B, Ciana G, Mengel E, M R Terk, C Martini, R J Wenstrup. Bone complications in children with Gaucher disease. Br J Radiol 2002; 75 Suppl 1: 37-44.
  11. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002; 75 Suppl 1: 2-12.
  12. Martine Regenboog, André B P van Kuilenburg, Joanne Verheij, Dorine W Swinkels, Carla E M Hollak.Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications. Blood Rev 2016; 30(6): 431-7.